AIM ImmunoTech Inc. (NYSE:AIM - Get Free Report) COO Peter W. Rodino III acquired 30,865 shares of the business's stock in a transaction on Monday, May 6th. The shares were purchased at an average price of $0.41 per share, for a total transaction of $12,654.65. Following the purchase, the chief operating officer now directly owns 212,583 shares of the company's stock, valued at $87,159.03. The transaction was disclosed in a filing with the SEC, which is available through this link.
AIM ImmunoTech Trading Up 1.2 %
Shares of NYSE AIM opened at $0.43 on Wednesday. The business has a 50 day simple moving average of $0.43 and a 200-day simple moving average of $0.44. AIM ImmunoTech Inc. has a twelve month low of $0.32 and a twelve month high of $0.75. The company has a market capitalization of $21.57 million, a price-to-earnings ratio of -0.71 and a beta of -0.11.
AIM ImmunoTech (NYSE:AIM - Get Free Report) last released its earnings results on Friday, March 29th. The company reported ($0.26) earnings per share for the quarter. AIM ImmunoTech had a negative net margin of 14,337.62% and a negative return on equity of 121.69%. The business had revenue of $0.07 million for the quarter.
AIM ImmunoTech Company Profile
(
Get Free Report)
The ONE AI Stock to own now. (It’s not Nvidia.)
From Weiss Ratings | Ad
Don’t panic — you haven’t missed the boat on AI.
In fact, it has barely launched.
Sure, the early stages of this boom were big …
But I believe the real wealth in AI has yet to be made …
Click here to see the presentation now.
AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
